Related Experiment Video
Updated: Jul 22, 2026
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Elevated circulation postsynaptic density protein 95 as a potential biomarker for predicting the diagnosis and
Yan Dong1, Zhangping He1, Haohai Lin1
1Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.
Insights
Plasma PSD95 levels are elevated in patients with cerebral infarction (CI) and correlate with disease severity. This suggests PSD95 may be a useful biomarker for diagnosing and predicting the prognosis of CI.
Area of Science:
- Biomarkers
- Neurology
- Clinical Diagnostics
Background:
- Cerebral infarction (CI) diagnosis and prognosis require reliable indices.
- Plasma PSD95 levels are a novel biomarker not yet explored for CI diagnosis or prognosis.
Purpose of the Study:
- To investigate the correlation between plasma PSD95 levels and clinical characteristics in CI patients.
- To assess the utility of plasma PSD95 levels in predicting the prognosis of CI.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma PSD95 levels in 105 CI patients and 80 controls.
- Neurological deficits were assessed using the National Institutes of Health Stroke Scale (NIHSS).
- Statistical analyses examined associations between PSD95, clinical parameters, and outcomes.
Main Results:
- Plasma PSD95 levels were significantly higher in CI patients than in controls (p < 0.01).
- In CI patients, PSD95 levels negatively correlated with activated partial thromboplastin time (APTT) (p < 0.05).
- PSD95 levels positively correlated with NIHSS scores at 6 months post-onset (p < 0.05).
Conclusions:
- Plasma PSD95 shows potential as a diagnostic biomarker for cerebral infarction.
- Plasma PSD95 may also serve as a prognostic biomarker for predicting outcomes in CI patients.
Purpose:
Indices for the diagnosis of cerebral infarction (CI) and the prediction of prognosis are essential for timely and appropriate management. Plasma PSD95 levels, as a novel biomarker, have not yet been utilized for the diagnosis and prognosis of cerebral infarction. The purpose of this study was to investigate the correlation between plasma PSD95 levels and clinical characteristics as well as prognosis in patients with CI.
Methods:
A total of 105 patients diagnosed with CI and 80 control group (CP) were enrolled. Plasma samples were collected and PSD95 levels were measured using enzyme-linked immunosorbent assay (ELISA). Neurological deficits in patients were evaluated using the National Institutes of Health Stroke Scale (NIHSS). Statistical analyses were conducted to assess the associations between plasma PSD95 levels, clinical parameters, and prognostic outcomes.
Results:
Plasma PSD95 levels were significantly elevated in CI patients compared to CP (p < 0.01). Furthermore, within the CI group, PSD95 levels exhibited a negative correlation with activated partial thromboplastin time (APTT) (p < 0.05) and a significant positive correlation with NIHSS scores assessed 6 months post-onset (p < 0.05).
Conclusion:
Plasma PSD95 may serve as a potential diagnostic and prognostic biomarker for cerebral infarction.
More Related Videos
08:27Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
Published on: March 11, 2020
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
